ProKidney Corp.
Status: Publicly traded
Direct answer
ProKidney Corp. is publicly traded on NASDAQ under the ticker PROK.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to...
Can you invest in ProKidney Corp.?
Yes. ProKidney Corp. is publicly traded on NASDAQ under the ticker PROK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ProKidney Corp.
Detailed equity research is provided by MarketSnap.